Healthcare Enterprise Group market a product called "Ebiox" which is one of a very few that can kill most bacteria including the MRSA superbug. HCEG has contracts with some NHS hospitals at present, but given the recent and current news and public attention, HCEG should be a good bet for a steady rise as more places seek to cut the number of casualties from this infection. HCEG also market abroad in USA, so the potential market for this unique product is massive indeed.

Well worth a punt IMHO

Check it out for yourself

Todays Shares Magazine has an article "Superbug Blitz".
Very dissapointing that HCEG nor Ebiox do not get a mention.

some big share trades today upto 45,000,000 so far

extract from Hansard today.

Mr. Lansley: I must remind the Secretary of State that the motion refers to many other ways in which failings in action have been laid bare by the NAO report. I will not be able to detail them all, but I want to ensure that the House is aware of them.

8 Sept 2004 : Column 790

"In a debate in July, my right hon. Friend the Member for Hitchin and Harpenden (Mr. Lilley) made specific reference to several new products and processes that have been offered to the NHS. He is not able to vouch for their effectivenessnor am Ibut that is why a rapid review process should be established. Ebiox is a non-alcohol cleansing product."

At long last things maybe beginning to happen.

http://www.publications.parliament.uk/pa/cm200304/cmhansrd/cm040908/debtext/40908-23.htm

Puzzled by the Shares article which mentions neither HCEG nor Bioquell (BQE). I suspect it is an article written by a journalist asked to do some brief research who has picked up just part of the story. Though I would check through this bb for enlightenment but may be just more confused. Can anyone give an objective view of (a) the relative merits of the different technologies attemting to tackle MRSA; (b) the timescale on profitability of the companies involved? I looked at HCEG when written up as a "penny share" in Shares, which was somewhat ludicrous when there are 2.9 billion of them (why so many?). The cap. of HCEG and Bioquell is broadly similar: HCEG have bought rights to EBIOX and it appears on-going research from the inventor; Bioquell have developed their own technology. The former appears to be primarily a marketing company, the latter a technology company. Bioquell's recent announcements concern academic research and two successful projects in French hospitals. Any insights?
Eric

Eric all info here.

http://www.advfn.com/cmn/fbb/thread.php3?id=6399024&from=1

Bioquell totally different product and believe they in effect steam clean rooms.They have also only cleaned a couple.The MRSA bug is carried thru the air,and 99% of us carry it to varying degrees,therefore hitting the source is the more important and that is where HCEG have a distinct advantage.

Below is a write up by citywire a while ago.
Citywire article
----------------
Bugs beware: Healthcare Enterprise is after you
Published: 09:42 Thr 26 Feb 2004
By Algernon Craig Hall, Secret Buying Correspondent

Big news for Healthcare Enterprise Group; the NHS has found its Ebiox product to be an effective solution for eradicating bacteria including the MRSA 'superbug'.

Testing has found Ebiox to be incredibly efficient at removing then destroying bacteria from two key areas hands and bacteria-laden work surfaces and floors.

The cleaning process using Ebiox also works in 30 seconds compared with normal standards which require a killing effect within five minutes.

Ebiox can now start to be used in hospitals which could lead to big orders. There is growing concern about the spread of disease inside hospitals, especially the so call superbug, and effective and quick decontamination has the potential to be very effective in tackling the problem.

Ebiox is one of a number of exciting projects that Healthcare has invested in. The company also makes and distributes occupational healthcare products such as Ebiox's decontaminants and first aid kits and is aiming to act as a consolidator in this fragmented sector. In addition it runs a related consultancy business which has a good US presence and is looking to expand in the UK.

Hope of some use.

Rumour of the day



Healthcare Enterprise, the AIM-listed medical products group, held steady at 1.89p, despite murmurs that it is set to disclose details of a new application for Ebiox in the US on or before its first-half results early next month. The Ebiox range comprises disinfectants used to combat hospital-acquired infections

http://www.timesonline.co.uk/newspaper/0,,2727-1308426,00.html

Quite interesting Ebiox should have an application in the US. Last week, on the Scottish news, the hospitals were discussing using a hand disinfectant sourced from the US - felt like ringing them up and suggesting they consider home grown product!! The US product looked to be serving exactly the same role as I understand Ebiox does.

If it's in The Times it must be correct. now upto 1.92p on bid

On the 9th Nov it'll be 2 months since the director dealings, perhaps then we'll have some long awaited news or confirmation of the 'the rumour'. Results are due too.

skids

Are results due soon-anybody know?? Another share that has never heard of good PR !!

Intrims were end of November last year so I assume similar for this year.

I think its worth buying for interim results in november & all the talk of MRSA superbug in news each day maybe some good news in pipeline?

The NHS will not be buying this Ebiox stuff until such time as it is shown to be better than the rival products. We know it meets all the Standards, but so does everything else (or they could not be sold on the market). If it's just the same people will not buy it unless it's cheaper. If it's better and so worth paying more for, you'd have thought there'd be some actual scientific clinically relevant evidence to prove it. There isn't. So no sales. Period.

$10 million dollar contract for the use of Ebiox in the USA


http://tinyurl.com/567hn

excellent news and bid moving up rapid.

numis morning meeting 8, nov. healthcare enterprises (1.86p) BUY target price 2.40p -us deal

This is a major deal and the implications of this deal are huge.IMHO this is just the start and based on this deal alone, SP will move up very fast.
Do your research and act before it is late. I hold shares in this company.

I think this is the best news for ages in this company, bought in this morning.
opto

Ticking up again this morning

see the bid went up to 2.0p following the announcement this morning ref Optiscope thought would post it incase anyone missed it.

Healthcare Enterprise Group PLC
10 November 2004


Healthcare Enterprise Group PLC

Optiscope Technologies Ltd Manufacturing Agreement

Optiscope time to market, accelerated through agreement with Wahl Optoparts


Healthcare Enterprise Group announces agreement with Wahl Optoparts GmbH, a
division of JENOPTIKS AG, for the development and manufacture of Optiscope, a
rigid endoscope based on proprietary technology. Optiscope is one of HCEG's key
portfolio technologies. JENOPTIKS AG is a world leader in photonics
technologies operating out of twenty countries with group sales of 3 billion.

Optiscope combines a revolutionary, patented optical design with innovative
plastic manufacturing methods and components, to produce a disposable clinical
product with no compromise to functionality. This gives Optiscope a significant
clinical advantage by removing the risk of cross contamination normally
associated with the re-use of expensive endoscopy equipment. Optiscope's
products will have high quality optics and are planned to be marketed at an
extremely attractive unit cost to hospitals, clinics and general practitioners.
In addition to the elimination of cross contamination, the low price will enable
bulk purchase, thereby streamlining procedures and reducing waiting times.

As part of this agreement, Wahl Optoparts has undertaken to perform a series of
laboratory tests on Optiscope's optic design and plans to introduce, together
with Optiscope, additional elements of its own expertise that will enhance both
the intellectual property and product functionality. It is thought that the
partnership with Wahl Optoparts will accelerate time to market for the finished
product by nearly a year. HCEG now anticipates that a commercial product will
be available for FDA inspection by mid 2005.

Optiscope is uniquely competitive in the endoscope market. The cost of a
comparable re-useable rigid endoscope is circa $3,000 per instrument. These are
frequently damaged during use, resulting in costly repairs. They also require
disinfection, decontamination, sterilisation and servicing following each
operation and, with a life span of approximately 200 operations, the estimated
cost per use is $40.

Gabriele Wahl-Multerer CEO, Wahl Optoparts GmbH, commented:

'The relationship with Optiscope provides Wahl Optoparts with an exciting
opportunity to develop our business in optical products and demonstrates our
commitment, as an OEM supplier with a closed process chain, to the international
medical market.

'Wahl's know-how and established procedures will ensure effective development
and manufacture, for example, through giving us 100% traceability throughout the
total production process. We are extremely excited to be associated with
Optiscope.'


Stuart Bruck, Executive Chairman, Healthcare Enterprise Group, commented:

'This relationship with Wahl represents a pivotal step for Optiscope and sets
out the timetable to market. Wahl, as part of the mighty JENOPTIKS, should be
viewed as major endorsement and confirms our original belief, that Optiscope has
significant market potential.

'Both Ebiox and Optiscope have received acclaim at the highest levels which will
provide HCEG shareholders with confidence in management's ability as we move to
roll out our new product portfolio.'

10 November 2004


Enquiries:

Healthcare Enterprise Group PLC 020 7351 7500
Stuart Bruck, Executive Chairman

College Hill 020 7457 2020
Nicholas Nelson/ Corinna Dorward